Browsing by Author "Harrigan, Richard P"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Comparable Pharmacokinetics of Generic Indinavir (Inhibisam) Versus Brand Indinavir (Crixivan) When Boosted With Ritonavir
    (2005-03-01) Zala, Carlos; Alexander, Christopher; Ochoa, Claudia; Guillemi, Silvia; Ting, Lillian; Bonner, Simon; Cahn, Pedro; Harrigan, Richard P; Montaner, Julio SG
    Letter to editor about Comparable Pharmacokinetics of Generic Indinavir (Inhibisam) Versus Brand Indinavir (Crixivan) When Boosted With Ritonavir
  • Thumbnail Image
    Item
    Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration
    (2005-04-26) Kantor, Rami; Katzenstein, David A; Efron, Brad; Carvalho, Ana Patricia; Wynhoven, Brian; Cane, Patricia; Clarke, John; Sirivichayakul, Sunee; Soares, Marcelo A; Snoeck, Joke; Pillay, Candice; Rudich, Hagit; Rodrigues, Rosangela; Holguin, Africa; Morris, Lynn; Vandamme, Anne-Mieke; Tanuri, Amilcar; Phanuphak, Praphan; Weber, Jonathan N; Pillay, Deenan; Harrigan, Richard P; Camacho, Ricardo; Schapiro, Jonathan M; Shafer, Robert W
    Background The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. Methods and Findings To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Conclusion Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.